Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

sodium-potassium adenosine triphosphatase inhibitor RX108

A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.
Synonym:Na+/K+-ATPase inhibitor RX108
sodium-potassium pump inhibitor RX108
Code name:RX 108
RX-108
RX108
Search NCI's Drug Dictionary